



Respiratory disease in Moldova



INTERNATIONAL
RESPIRATORY
COALITION

The International Respiratory Coalition (IRC) was founded to tackle one of global health's most overlooked challenges: the burden of respiratory disease.

We bring together national coalitions of health professionals, patient advocates and policymakers to develop and implement national respiratory health strategies that address prevention, treatment and care.

The ultimate goal is to reduce respiratory disease-related mortality by a third globally by 2030, in line with the UN Sustainable Development Goals.

The Coalition for Respiratory Health from the Republic of Moldova was founded in November 2024 and joined the IRC the same year. It brings together medical professionals to promote respiratory health through education, prevention and interdisciplinary collaboration.

Its key initiatives and upcoming milestones include:

- The launch of Moldova's first Sleep Medicine Centre
- Growth of international partnerships
- Development of a National Respiratory Health Strategy
- Expanding national COPD and asthma screening
- Strengthening Moldova's respiratory health networks
- Improving patient education and treatment adherence

374.8
thousand
people living with
respiratory
diseases

Societal economic cost by disease:



Asthma
639.1 million
MDL



COPD
2.6 billion
MDL



Lung cancer
3.3 billion
MDL



Lower respiratory
tract infections
3.3 billion
MDL



Mesothelioma
23.9 million
MDL



Tuberculosis
592.1 million
MDL



Interstitial lung
disease
23.4 million
MDL



COVID-19
2 billion
MDL



Pulmonary arterial
hypertension
2.7 million
MDL

3.2
thousand
deaths from
respiratory
diseases

102
thousand
healthy life years
lost to respiratory
diseases

12.5
billion MDL
societal
economic cost
of respiratory
diseases

The IRC is made possible with the contributions of various stakeholders: IRC leadership is provided by the European Respiratory Society and European Lung Foundation; Additional stakeholders include: the IRC National Coalitions and the Global Allergy and Airways Patient Platform; Funding support is provided by AstraZeneca, Chiesi Group, GSK, MSD, Sanofi and Regeneron.

Data taken from IRC Lung Facts <https://international-respiratory-coalition.org/lung-facts/>

Published:
September 2026